QQQ   312.03 (+1.93%)
AAPL   159.83 (+1.27%)
MSFT   278.95 (+2.45%)
META   205.66 (+2.93%)
GOOGL   105.73 (+2.28%)
AMZN   99.58 (+0.89%)
TSLA   192.70 (+0.81%)
NVDA   271.65 (+2.63%)
NIO   9.35 (+2.86%)
BABA   86.49 (+3.40%)
AMD   101.31 (+3.82%)
T   18.48 (+0.49%)
F   11.57 (+0.78%)
MU   61.45 (+5.64%)
CGC   1.92 (+1.86%)
GE   91.54 (+2.18%)
DIS   96.39 (+1.57%)
AMC   4.45 (+2.53%)
PFE   40.28 (+0.67%)
PYPL   73.03 (-1.76%)
NFLX   317.75 (+8.12%)
QQQ   312.03 (+1.93%)
AAPL   159.83 (+1.27%)
MSFT   278.95 (+2.45%)
META   205.66 (+2.93%)
GOOGL   105.73 (+2.28%)
AMZN   99.58 (+0.89%)
TSLA   192.70 (+0.81%)
NVDA   271.65 (+2.63%)
NIO   9.35 (+2.86%)
BABA   86.49 (+3.40%)
AMD   101.31 (+3.82%)
T   18.48 (+0.49%)
F   11.57 (+0.78%)
MU   61.45 (+5.64%)
CGC   1.92 (+1.86%)
GE   91.54 (+2.18%)
DIS   96.39 (+1.57%)
AMC   4.45 (+2.53%)
PFE   40.28 (+0.67%)
PYPL   73.03 (-1.76%)
NFLX   317.75 (+8.12%)
QQQ   312.03 (+1.93%)
AAPL   159.83 (+1.27%)
MSFT   278.95 (+2.45%)
META   205.66 (+2.93%)
GOOGL   105.73 (+2.28%)
AMZN   99.58 (+0.89%)
TSLA   192.70 (+0.81%)
NVDA   271.65 (+2.63%)
NIO   9.35 (+2.86%)
BABA   86.49 (+3.40%)
AMD   101.31 (+3.82%)
T   18.48 (+0.49%)
F   11.57 (+0.78%)
MU   61.45 (+5.64%)
CGC   1.92 (+1.86%)
GE   91.54 (+2.18%)
DIS   96.39 (+1.57%)
AMC   4.45 (+2.53%)
PFE   40.28 (+0.67%)
PYPL   73.03 (-1.76%)
NFLX   317.75 (+8.12%)
QQQ   312.03 (+1.93%)
AAPL   159.83 (+1.27%)
MSFT   278.95 (+2.45%)
META   205.66 (+2.93%)
GOOGL   105.73 (+2.28%)
AMZN   99.58 (+0.89%)
TSLA   192.70 (+0.81%)
NVDA   271.65 (+2.63%)
NIO   9.35 (+2.86%)
BABA   86.49 (+3.40%)
AMD   101.31 (+3.82%)
T   18.48 (+0.49%)
F   11.57 (+0.78%)
MU   61.45 (+5.64%)
CGC   1.92 (+1.86%)
GE   91.54 (+2.18%)
DIS   96.39 (+1.57%)
AMC   4.45 (+2.53%)
PFE   40.28 (+0.67%)
PYPL   73.03 (-1.76%)
NFLX   317.75 (+8.12%)
NASDAQ:KURA

Kura Oncology - KURA Stock Forecast, Price & News

$12.01
-0.02 (-0.17%)
(As of 03/23/2023 01:51 PM ET)
Add
Compare
Today's Range
$11.96
$12.32
50-Day Range
$10.71
$14.60
52-Week Range
$10.30
$19.93
Volume
246,363 shs
Average Volume
647,649 shs
Market Capitalization
$821.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.20

Kura Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
156.6% Upside
$31.20 Price Target
Short Interest
Bearish
10.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.23mentions of Kura Oncology in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$73,270 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.38) to ($2.24) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

545th out of 986 stocks

Pharmaceutical Preparations Industry

263rd out of 477 stocks


KURA stock logo

About Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Stock News Headlines

Geron (GERN) Gets a Buy from Wedbush
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Q4 2022 Kura Oncology Inc Earnings Call
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Kura Oncology's Earnings Outlook
Kura Wins FDA Clearance for Tumor Treatment
H.C. Wainwright Keeps Their Buy Rating on Kura Oncology (KURA)
Cramer Is Holding This Biotech Stock
See More Headlines
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Company Calendar

Last Earnings
2/23/2023
Today
3/23/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.20
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+154.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-135,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.28 per share

Miscellaneous

Free Float
64,743,000
Market Cap
$837.71 million
Optionable
Optionable
Beta
0.93

Key Executives

  • Troy E. Wilson
    Chairman, President, CEO & Chief Financial Officer
  • Kathleen Ford
    Chief Operating Officer
  • Stephen Dale
    Chief Medical Officer
  • Mollie Leoni
    Senior Vice President-Clinical Development
  • Thomas Doyle
    Chief Accounting Officer & Senior VP-Finance













KURA Stock - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KURA shares.
View KURA analyst ratings
or view top-rated stocks.

What is Kura Oncology's stock price forecast for 2023?

5 Wall Street analysts have issued 1 year price objectives for Kura Oncology's shares. Their KURA share price forecasts range from $25.00 to $40.00. On average, they expect the company's share price to reach $31.20 in the next year. This suggests a possible upside of 159.4% from the stock's current price.
View analysts price targets for KURA
or view top-rated stocks among Wall Street analysts.

How have KURA shares performed in 2023?

Kura Oncology's stock was trading at $12.41 at the start of the year. Since then, KURA shares have decreased by 3.1% and is now trading at $12.03.
View the best growth stocks for 2023 here
.

Are investors shorting Kura Oncology?

Kura Oncology saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 7,090,000 shares, an increase of 5.3% from the February 13th total of 6,730,000 shares. Based on an average daily volume of 821,900 shares, the days-to-cover ratio is currently 8.6 days. Currently, 11.0% of the shares of the stock are sold short.
View Kura Oncology's Short Interest
.

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our KURA earnings forecast
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) released its quarterly earnings data on Thursday, February, 23rd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.09.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (4.64%), T. Rowe Price Investment Management Inc. (3.99%), Dimensional Fund Advisors LP (2.54%), Artal Group S.A. (2.54%), Victory Capital Management Inc. (2.27%) and Victory Capital Management Inc. (2.27%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Marc Grasso, Thomas James Doyle and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $12.03.

How much money does Kura Oncology make?

Kura Oncology (NASDAQ:KURA) has a market capitalization of $823.33 million. The company earns $-135,840,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Kura Oncology have?

The company employs 121 workers across the globe.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for the company is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com.

This page (NASDAQ:KURA) was last updated on 3/23/2023 by MarketBeat.com Staff